A novel NK cell engager targeting the activating receptors, NKp46 and CD16, on NK cells and a tumor antigen on cancer cells has been reported to show higher killing potency than that of any therapeutic antibodies targeting the same tumor antigen21. Here, NCR1 is linked to neoplasm.